Limits...
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D - J Oncol (2009)

Bottom Line: In contrast, high MMP9 mRNA expression was found to be significantly associated with objective response.In conclusion, CCRT is feasible and active.However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.

ABSTRACT
Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive role of several biomarkers in an unselected cohort of patients treated with concomitant radiotherapy, weekly cisplatin, and cetuximab (CCRT). We identified 37 patients treated with this approach, of which 13 (35%) achieved a complete response and 10 (27%) achieved a partial response. Severe side effects were mainly leucopenia, dysphagia, rash, and anemia. Tumor EGFR, MET, ERCC1, and p-53 protein and/or gene expression were not associated with treatment response. In contrast, high MMP9 mRNA expression was found to be significantly associated with objective response. In conclusion, CCRT is feasible and active. MMP9 was the only biomarker tested that appears to be of predictive value in cetuximab treated patients. However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort.

No MeSH data available.


Related in: MedlinePlus

Waterfall for the response of target lesions according to RECIST criteria (N = 24).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2801452&req=5

fig1: Waterfall for the response of target lesions according to RECIST criteria (N = 24).

Mentions: Following the completion of CCRT, response was evaluated according to the RECIST criteria for 24 out of 37 patients (Figure 1). For 6 of these patients response was evaluated by PET as well. For one of the patients, response was classified as partial by RECIST, while PET was free of tumor, thus this patient was considered to be a complete responder in the overall response evaluation. In one additional case, response was evaluated by PET only.


MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D - J Oncol (2009)

Waterfall for the response of target lesions according to RECIST criteria (N = 24).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2801452&req=5

fig1: Waterfall for the response of target lesions according to RECIST criteria (N = 24).
Mentions: Following the completion of CCRT, response was evaluated according to the RECIST criteria for 24 out of 37 patients (Figure 1). For 6 of these patients response was evaluated by PET as well. For one of the patients, response was classified as partial by RECIST, while PET was free of tumor, thus this patient was considered to be a complete responder in the overall response evaluation. In one additional case, response was evaluated by PET only.

Bottom Line: In contrast, high MMP9 mRNA expression was found to be significantly associated with objective response.In conclusion, CCRT is feasible and active.However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.

ABSTRACT
Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive role of several biomarkers in an unselected cohort of patients treated with concomitant radiotherapy, weekly cisplatin, and cetuximab (CCRT). We identified 37 patients treated with this approach, of which 13 (35%) achieved a complete response and 10 (27%) achieved a partial response. Severe side effects were mainly leucopenia, dysphagia, rash, and anemia. Tumor EGFR, MET, ERCC1, and p-53 protein and/or gene expression were not associated with treatment response. In contrast, high MMP9 mRNA expression was found to be significantly associated with objective response. In conclusion, CCRT is feasible and active. MMP9 was the only biomarker tested that appears to be of predictive value in cetuximab treated patients. However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort.

No MeSH data available.


Related in: MedlinePlus